ArticleCognitive neurodynamics2022
Neurodegenerative diseases-Caps: a capsule network based early screening system for the classification of neurodegenerative diseases.
Article in Cognitive neurodynamics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advancements in Neuroimaging-Based Alzheimer's Disease Prediction Using Deep Learning Approaches in e-Health: A Systematic Review.Health science reports · 2025Review
- Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The two most generally diagnosed Neurodegenerative diseases are the Alzheimer and Parkinson diseases. So this paper presents a fully automated early screening system based on the Capsule network for the classification of these two Neurodegenerative diseases. In this study, we hypothesized that the Neurodegenerative diseases-Caps system based on the Capsule network architecture accurately performs the multiclass i.e. three class classification into either the Alzheimer class or Parkinson class or Healthy control and delivers better results in comparison other deep transfer learning models. The real motivation behind choosing the capsule network architecture is its more resilient nature towards the affine transformations as well as rotational & translational invariance, which commonly persists in the medical image datasets. Apart from this, the capsule networks overcomes the pooling layers related deficiencies from which conventional CNNs are mostly affected and unable to delivers accurate results especially in the tasks related to image classification. The various Computer aided systems based on machine learning for the classification of brain tumors and other types of cancers are already available. Whereas for the classification of Neurodegenerative diseases, the amount of research done is very limited and the number of persons suffering from this type of diseases are increasing especially in developing countries like India, China etc. So there is a need to develop an early screening system for the correct multiclass classification into Alzheimer's, Parkinson's and Normal or Healthy control cases. The Alzheimer disease and Parkinson progression (ADPP) dataset is used in this research study for the training of the proposed Neurodegenerative diseases-Caps system. This ADPP dataset is developed with the aid of both the Parkinson's Progression Markers Initiative (PPMI) and Alzheimer's disease Neuroimaging Initiative (ADNI) databases. There is no such early screening system exist yet, which can perform the accurate classification of these two Neurodegenerative diseases. For the sake of genuine comparison, other popular deep transfer learning models like VGG19, VGG16, ResNet50 and InceptionV3 are implemented and also trained over the same ADPP dataset. The proposed Neurodegenerative diseases-Caps system deliver accuracies of 97.81, 98, 96.81% for the Alzheimer, Parkinson and Healthy control or Normal cases with 70/30 (training/validation split) and performs way better as compare to the other popular Deep transfer learning models. Supplementary Information: The online version contains supplementary material available at 10.1007/s11571-022-09787-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.